Background. Influenza is a significant cause of morbidity, and vaccination is the preferred preventive strategy. Data regarding the preferred influenza vaccine type among adults are limited.
Influenza is a significant cause of morbidity and mortality, with approximately 36 000 deaths and 226 000 hospitalizations annually in the United States [1, 2] . Additionally, influenza contributes to significant lost work days each year, impacting both economic productivity and military force readiness [3, 4] . Vaccination is currently the preferred strategy for the prevention of influenza [5, 6] .
In the United States, 2 types of influenza vaccines are available: a live, attenuated influenza vaccine (LAIV) and a trivalent inactivated influenza vaccine (TIV). Vaccine efficacy varies by characteristics of the host (eg, age, underlying immunosuppressive conditions) and the vaccine (eg, the similarity, or "match," between the vaccine and circulating strains). The type of influenza vaccine (LAIV, TIV) may also impact the efficacy in preventing influenza and influenza-like illness (ILI). In children and adolescents (aged 6 months-18 years), LAIV has been shown to be superior to TIV in several studies [7] [8] [9] , and in a meta-analysis [10] LAIV was shown to be superior to TIV in preventing both ILI and culture-proven influenza [11, 12] . However, results have been variable among adults, depending on the season and population studied, and several studies did not adequately control for potential confounders [13] [14] [15] [16] [17] [18] [19] .
Because the Advisory Committee on Immunization Practices (ACIP) currently recommends annual influenza vaccination for all adults regardless of underlying medical conditions [6] , it is critical to determine the most effective vaccine type for adults. To provide information on the preferred vaccine among healthy adults, we performed a study comparing LAIV with TIV on ILI and influenza/pneumonia events among US military members during 3 consecutive influenza seasons.
METHODS

Study Population
We conducted a retrospective cohort study among US military members who were participants in a large Department of Defense (DoD) study on health behaviors (ie, Millennium Cohort Study) [20] and completed a survey within 2 years of the vaccination date. Data from the Millennium Cohort Study were utilized to control for potential confounders, which was a limitation of prior studies [15, 17] . Participants were active-duty members stationed in the contiguous United States at the beginning of the influenza season who had received influenza vaccination during 2006-2009; active-duty members are required to receive annual influenza vaccination, with issuance of TIV or LAIV often based on available supply. Unvaccinated members were excluded due to high vaccine coverage rates and potential uncertainties regarding vaccine status. Nonactive-duty military personnel, deployers, and members stationed on ships or overseas were excluded because these groups may be exposed to influenza subtypes not covered by the vaccine and outcomes of interest may be missed in existing databases. Additionally, military recruits were excluded because this group has unique exposure risks for respiratory illnesses.
Participants were followed from the time of influenza vaccination (administered 1 September-30 November of each season) until the end of the influenza season (19 May 2007 , 17 May 2008 , and 28 March 2009 given the emergence of the pandemic H1N1 strain), occurrence of an ILI, or censoring event [21, 22] . Individuals were right censored if they deployed or transferred outside the continental United States.
All participants were 18-49 years of age at the time of vaccination because LAIV is limited to adults ≤49 years of age. Exclusion criteria included a medical diagnosis of asthma, chronic bronchitis, emphysema, history of shortness of breath, diabetes mellitus, human immunodeficiency virus (HIV) infection, or pregnancy, because LAIV use may be contraindicated and these conditions may result in suboptimal vaccine responses. The study was approved by the Naval Health Research Center institutional review board.
Study Outcomes
Outcomes were defined a priori and based on healthcare encounter data from military and civilian medical facilities. ILI was chosen as the primary outcome because laboratory testing for influenza virus is not commonly used and because ILI has both medical and occupational significance. An ILI was defined by International Classification of Diseases, Ninth Revision (ICD-9) codes based on previous studies and shown to be related to culture-confirmed influenza in military service members (079.99, 382.9, 460, 461.9, 465.8, 465.9, 466.0, 486, 487.0, 487.1, 487.8, 490, 780.6, and 786.2) [15, 23] . We also examined secondary outcomes of (1) a diagnosis of influenza (487.0, 487.1, and 487.8) and/or pneumonia (486; because the latter may be a complication of influenza), and (2) diagnosis of influenza. In addition, dispensed anti-influenza medications (ie, oseltamivir, zanamivir, amantadine, or rimantadine) were utilized for the diagnosis of ILI and influenza.
Outcomes were captured starting on the first day of the flu season, and only the first ILI event per participant in each influenza season was used in the analyses. Participants with an event during the current influenza season, but before the receipt of vaccination and those occurring ≤14 days postvaccination, were excluded from analyses to allow adequate time for development of an immune response. Participants could contribute to more than 1 influenza season if they received vaccine and met the inclusion/exclusion criteria during each season. Three consecutive Northern Hemisphere influenza seasons were evaluated. Seasons 2006 Seasons -2007 Seasons and 2008 Seasons -2009 were analyzed together due to a reported good match between vaccine and circulating strains, and the 2007-2008 season was analyzed separately because of a suboptimal match that was due to slight antigenic drift [16, 22, 24, 25] .
Data Collection
Information on sociodemographic and military-related characteristics were obtained from the Defense Manpower Data Center (DMDC) in Monterey, California. These data included age, sex, self-reported race/ethnicity, marital status, education, service branch, military pay grade (enlisted, officer), duty station (coded into 4 geographic locations), duty occupation, and deployment history. Data on preexisting medical conditions used as exclusion criteria were obtained from the Millennium Cohort Study and medical records. Additionally, the Pharmacy Data Transaction Service was utilized to exclude participants receiving medications for diabetes mellitus or HIV and to capture anti-influenza medications. Data on tobacco use (defined as both ≥100 cigarettes in a lifetime and use within the last year) and potential alcohol problems (defined as an affirmative answer to 1 or more of the 5 Patient Health Questionnaire alcohol questions) [26] were collected from the Millennium Cohort Study. Type and date of influenza vaccinations were obtained from DMDC. The outcomes of interest (ILI, influenza, pneumonia) were determined by review of the Military Health System Data Repository, which contains all outpatient and inpatient encounters from military treatment facilities and TRICARE network providers.
Statistical Analyses
Descriptive statistics are presented as numbers (percentages) for categorical variables and medians (interquartile range, IQR) for continuous variables. The associations between the covariates and primary outcome were assessed for significance using logistic regression (for categorical variables) and the Wilcoxon rank sum test (for continuous variables). Crude incidence rates of ILI per 1000 persons per season were compared between the LAIVand TIV-immunized groups. Cox proportional hazard modeling was utilized to evaluate the unadjusted and adjusted risk for the primary study outcome (ILI) by the vaccine type (LAIV, TIV) as well as other covariates of interest (sociodemographic, geographic, and behavioral factors). In order to adjust for the potential effects of individuals contributing to multiple seasons, a robust variance estimator was used. To account for individuals receiving the vaccination at different times in relation to the influenza season, a left truncated model was developed starting with survival time at 1 September of the influenza season and truncating on the date of vaccination plus 14 days. A final multivariable model was derived using a backward, stepwise approach and was adjusted for covariates that were significantly associated with the outcome (P < .05) or that confounded the relationship between vaccine type and ILI by ≥10%. In addition, interactions were evaluated between vaccine type and sex, service branch, and influenza season. Results of the Cox models were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Separate models were created for the (1) "wellmatched" seasons (2006-2007 and 2008-2009 ) and (2) the season with an antigenic drift labeled "suboptimally matched" (2007) (2008) . Additionally, separate models were created for the secondary outcomes of influenza/pneumonia and influenza. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Inc, Cary, NC). 
RESULTS
Study Population Characteristics
Influenza-Like Illness Events
A total of 5893 ILI events were diagnosed during 2006-2009, for an overall crude ILI incidence rate of 141.1 cases per 1000 persons-season. Weekly data for ILI cases demonstrated a similar pattern to that of positive influenza isolates in the general population using Centers for Disease Control and Prevention (CDC) surveillance data ( Figure 1) . ILI rates for LAIV and TIV were 138.5 and 127.0 cases per 1000 person-seasons, respectively, during well-matched seasons. In the univariable model during the well-matched seasons, type of vaccine was not significantly associated with the development of an ILI (HR, 1.02; 95% CI, .95-1.11; Table 2 ). In the final multivariable model adjusted for all significant covariates, the risk of ILI did not significantly differ between LAIV and TIV (HR, 0.97; 95% CI, .90-1.06) ( During the suboptimally matched season, the crude ILI rates were 149.6 per 1000 person-season for LAIV recipients and 165.1 per 1000 person-season for TIV recipients. In the univariable and multivariable models, vaccine type was not associated with the risk of ILI (HR, 0.94; 95% CI, .85-1.04 and HR, 1.00; 95% CI, .90-1.11, respectively). Factors significantly associated with a decreased risk of ILI during this season were male sex, unmarried status, officer rank, and non-Air Force service branches (Table 2 ).
Given previous reports that younger adults may have varying responses to LAIV and TIV [15, 17] , we examined the subgroup of 18-to 24-year-old service members (n = 10 212) during the well-matched seasons. In the final multivariable model (adjusted for all covariates), there was no significant association with type of influenza vaccine and ILI events (HR 1.09 for LAIV compared with TIV; 95% CI, .95-1.25).
Influenza and Pneumonia Events
A total of 168 cases of influenza and/or pneumonia were noted during the well-matched seasons, with a crude rate of 6.0 and 5.2 per 1000 person-seasons for LAIV and TIV recipients, respectively. In the final Cox proportional hazards model, the risk for influenza/pneumonia was not significantly different between vaccine groups (HR, 1.15; 95% CI, .78-1.69; (Table 3) .
There were 76 influenza cases during the well-matched seasons, with a crude rate of 2.6 cases per 1000 personseasons among both LAIV and TIV recipients. In the final multivariable model, vaccine type was not associated with influenza events (HR, 0.98; 95% CI .56-1.72). Likewise, during the suboptimally matched season, the rate of influenza was 6.5 and 8.5 cases per 1000 person-seasons for LAIV and TIV recipients, respectively, and there was no association in the final model (HR, 0.79; 95% CI .50-1.24; Table 3 ).
DISCUSSION
Our multiseason study found that LAIV and TIV had similar overall effectiveness against ILI and influenza/pneumonia events during 2006-2009. These data suggest that healthy adults achieve similar protection from both vaccine types and support the current ACIP recommendations for influenza vaccination among this population.
The most important step in reducing influenza-related morbidity and mortality in a population is to ensure vaccination [6] . An additional consideration is the type of vaccine to use in specific populations. Although several studies have demonstrated the superior efficacy of LAIV compared with TIV in children and adolescents [7] [8] [9] [10] [11] [12] , there is no consensus regarding the most efficacious vaccine type among adults. Currently, decisions regarding vaccine type among adults are often based on supply and preferences regarding administration route and potential side effects [27] . For example, LAIV has increasingly been utilized by the US military due to its relative ease of administration and ample supply [17] . The current US military recommendations regarding influenza vaccination notes that either LAIV or TIV may be used among adults without contraindications to LAIV, which are similar to ACIP recommendations [6, 28] . Data on the most effective type of influenza vaccination is paramount to ensure a healthy and fit population and military force and to inform DoD and other agencies about the optimal influenza vaccine type among healthy adults.
Our study found that LAIV and TIV had similar rates of ILI, influenza/pneumonia, and influenza events. A prior study using existing medical records of US military personnel during earlier influenza seasons (2004) (2005) (2006) (2007) found that TIV offered more protection from influenza and/or pneumonia (diagnosed using ICD-9 codes) than did LAIV [17] . A second study in military members found that nonrecruits who received TIV had lower rates of ILI, whereas LAIV was more effective among recruits [15] . However, these studies did not control for several important confounders (tobacco use, occupation, or geographic area) and utilized different methodologies to select their study populations. For example, we excluded persons outside the contiguous United States (eg, Navy afloat, service members receiving sea pay, and those vaccinated while deployed) as these populations are more likely to receive TIV (rather than LAIV) and less likely to have medical events recorded in the electronic data files (confirmed using data from the medical data repository and DMDC). We reanalyzed our data without these exclusions and found estimates similar to those from prior studies [15, 17] , suggesting that deployers and personnel at sea may have influenced prior results regarding TIV's effectiveness. Regarding the general population, randomized, placebo-controlled studies on university campuses in Michigan showed that TIV was either similarly or more efficacious than LAIV [13, 14, 16] . Our study adds important data to the literature by providing robust population-based data that was controlled for many potential confounders (obtained from both medical/military records and participant questionnaires) and encompassed 3 sequential seasons. Our study suggests that among healthy adults without significant comorbidities, vaccine type is not a differentiating factor for ILI and influenza/pneumonia events during the influenza season. Overall, these data suggest that adults can be vaccinated with either vaccine type, which potentially simplifies vaccination protocols and focuses attention on the key factor of ensuring vaccination itself. The reasons for the potential varying effectiveness of vaccine types based on the population (children compared with adults) may be the result of the divergent immune responses elicited. TIV is administered intramuscularly with rapid introduction into the bloodstream and induction of serum antibodies, whereas the intranasal administration of LAIV induces both humoral (serum and mucosal immunoglobulin A antibodies) and cell-mediated immune responses [29, 30] . As such, LAIV may be superior as a priming vaccine among young persons (eg, aged <18 years and perhaps young military recruits) who have little preexisting immunity [17] . As a boosting vaccine, TIV's efficacy is higher in adults relative to children (likely due to preexisting immunity), resulting in its comparable effectiveness seen in adults.
In our study, the impact of ILI/influenza events was substantial-14% of this healthy well-vaccinated adult population had a medical visit for an ILI and 0.7% for influenza/pneumonia during each season. The economic burden of all influenza events in the United States is an estimated $87 billion per year due to work absenteeism, healthcare-associated costs, and premature mortality [3, 31] . Even among healthy adults aged 18-49 years without predisposing medical conditions (similar to our population), influenza causes millions of healthcare visits each year [31] . Additionally, among military members, such events may have implications for national security [4, 32] . Our study has some limitations. The study's outcomes were based on ICD-9 codes, rather than culture-or polymerase chain reaction-confirmed influenza; however, ICD-9 codes previously have been correlated with influenza events [15, 17, 23] . Our study focused on ILI events requiring a medical visit and did not capture outcomes for which the participant did not seek care. Given our young, healthy population, the number of confirmed influenza and/or pneumonia events was small; hence, we may have missed potential associations for these outcomes. However, our primary model had a power of 80% to detect an HR as low as 1.13. Data collected from military records and participant questionnaires may be subject to misclassification errors and reporting biases, but these were likely nondifferential in nature. Finally, our study focused on a highly vaccinated population of healthy adults and did not evaluate high-risk adults such as those aged ≥50 [19] or with immunocompromising conditions (eg, HIV, diabetes, pregnancy). More research on the preferred vaccine in these populations and adults with negative health behaviors (eg, alcohol and smoking) is needed.
In summary, recommendations for influenza vaccination have recently expanded to include all adults. Our study demonstrated that LAIV and TIV have similar efficacy in preventing ILI and influenza/pneumonia events among healthy 18-to 49-year-olds. These data provide valuable information for providers and policy makers regarding the influenza vaccination among healthy adults.
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